Sunshine Biopharma INC 10-Q quarterly reports

Sunshine Biopharma Inc. reported a decrease in revenue for Q2 2026 compared to the prior year, alongside continued net losses, but highlighted progress in its proprietary drug development pipeline and a strengthened cash position.

Sunshine Biopharma Inc. reported an 11.6% increase in Q3 2025 revenue and a 24.0% reduction in net loss, driven by enhanced marketing and improved cost of goods sold.

Sunshine Biopharma Inc. reported a wider net loss in Q2 2025 due to a significant intangible asset impairment and increased operating expenses, despite revenue growth and improved gross profit margins.

Sunshine Biopharma saw an increase in revenue for Q1 2025, but losses continue as the company focuses on generic drug sales and proprietary drug development.

Sunshine Biopharma saw a significant increase in revenue during the third quarter of 2024, but the company still reported a net loss.

Sunshine Biopharma's Q2 2024 results show a significant increase in revenue driven by its generic pharmaceutical segment, despite ongoing losses.

Sunshine Biopharma saw a significant increase in revenue during the second quarter of 2024, primarily due to expanded sales of generic pharmaceuticals.

Sunshine Biopharma saw a 54% increase in sales in the first quarter of 2024 compared to the same period last year, driven by new product launches and expanded marketing efforts, but still reported a net loss.